Yoga as a Supportive Therapy for Patients With Hypertension

Yoga as a Supportive Therapy for Patients With Hypertension: A Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02727140

Enrollment

Registered

2016-04-04

Start date

2016-05-31

Completion date

2017-04-30

Last updated

2017-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The proposed study aims to investigate the feasibility, effectiveness, and perceived benefit of a supportive hatha yoga intervention for patients with hypertension using antihypertensive drugs. Patients will be randomized into 3 groups comparing hatha yoga with yoga postures, breathing and relaxation techniques to a hatha yoga intervention without yoga postures (only breathing and relaxation techniques) as well as to a wait list control group.

Interventions

BEHAVIORALYoga with Asana (yoga postures)

Yoga intervention consisting of asana, breathing and relaxation, meditation

BEHAVIORALYoga without Asana (yoga postures)

Yoga intervention without asanas, consisting only of breathing, relaxation and meditation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* essential Hypertension * stable antihypertensive medication during the next 6 months

Exclusion criteria

* pregnancy or breast feeding * simultaneous participation in further clinical intervention trials * regular yoga practice in the past 12 months * serious mental illness (severe depression, severe addiction, psychosis) * manifest coronary heart disease that has been treated in the past 3 months or myocardial infarction, embolism of pulmonary arteries or stroke in the past 3 months * heart failure ≥ state 1 New York Heart Association (NYHA) * peripheral arterial occlusive disease ≥ state 1 * renal insufficiency \> state 2, glomerular filtration rate \< 60 ml/min/1,73m² according to he National Kidney Foundation (NKF)

Design outcomes

Primary

Measure	Time frame
24 h mean value of systolic and diastolic blood pressure	12 weeks

Secondary

Measure	Time frame	Description
Adverse Events	12 weeks	—
24 h mean value of systolic and diastolic blood pressure	28 weeks	—
Health-related Quality of Life	12 weeks	Short Form 36 Health Survey Questionnaire (SF-36)
Physical activity	12 weeks	Baecke Physical Activity Questionnaire
Subjective Stress	12 weeks	Cohen Perceived Stress Scale (CPSS)
Nutrition habits	12 weeks	Five a Day Food Frequency Questionnaire
Emotional Distress	12 weeks	Hospital Anxiety and Depression Scale (HADS)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026